Log in
Enquire now
‌

US Patent 7959925 Trimeric OX40-immunoglobulin fusion protein and methods of use

Patent 7959925 was granted and assigned to Providence Health System on June, 2011 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Current Assignee
‌
Providence Health System
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
7959925
Date of Patent
June 14, 2011
Patent Application Number
12618678
Date Filed
November 13, 2009
Patent Citations Received
‌
US Patent 12090183 Methods of treating solid or lymphatic tumors by combination therapy
0
‌
US Patent 11746148 Antibody molecules comprising a single-domain antigen-binding site and Fab fragments
‌
US Patent 11945869 PD-1 single domain antibodies and therapeutic compositions thereof
0
‌
US Patent 12012459 OX40-binding polypeptides and uses thereof
0
Patent Primary Examiner
‌
Shulamith H. Shafer
Patent abstract

Compositions including a trimeric OX-40 fusion protein are disclosed. Also disclosed are methods for enhancing the immune response of a mammal to an antigen by engaging the OX-40 receptor on the surface of T-cells involving administering to the mammal a composition comprising a trimeric OX-40 fusion protein and a pharmaceutically acceptable carrier.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 7959925 Trimeric OX40-immunoglobulin fusion protein and methods of use

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.